We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ovid Therapeutics is selling the global rights to an investigational drug for rare epileptic diseases to Takeda Pharmaceutical in a deal worth potentially $856 million — as Ovid shifts gears and focuses on research of new neurological therapies. Read More
New Mexico’s attorney general has filed a lawsuit against Gilead Sciences, Teva Pharmaceuticals and Bristol Myers Squibb (BMS) over alleged anticompetitive practices that caused the state to significantly overpay for HIV medications. Read More
With Johnson & Johnson struggling to meet its COVID-19 vaccine supply commitments for the U.S., pharma titan Merck will provide its support to ramp up manufacturing of the one-shot vaccine, the Biden administration said Tuesday. Read More
Merck KGaA will pay Switzerland-based Debiopharm up to $1.08 billion (€900 million) for the global rights to Xevinapant, an investigational head and neck cancer treatment. Read More
The U.S. has begun vaccinations with Johnson & Johnson’s (J&J) single-dose vaccine following the FDA’s authorization over the weekend but confronting a small initial rollout the drugmaker is accelerating dose production and working with multiple manufacturers in the U.S. and at sites in Europe, India and South Africa to meet its supply commitments. Read More
A Government Accountability Office (GAO) review of COVID-19 vaccine development efforts found that vaccine producers are facing significant manufacturing hurdles as they scale up operations. Read More
Fresenius Kabi Oncology (FKO) has agreed to plead guilty to hiding and destroying records prior to a 2013 FDA inspection and will hand over $50 million in fines and forfeiture, the U.S. Department of Justice revealed. Read More
Merck plans to acquire Massachusetts-based Pandion Therapeutics for an estimated $1.85 billion to broaden its portfolio of autoimmune disease therapies. Read More
Despite facing significant delays in supplying the European Union with its ordered AstraZeneca (AZ)/Oxford COVID-19 vaccine doses, AZ has said that it is using a large number of doses made via its international supply chain to meet its second-quarter supply commitments with Europe. Read More